Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122

NU SKIN ENTERPRISES, INC.

NUS

Watch

Latest revenue

$320.6M

as of 2026-03-31

Latest net income

$1.8M

as of 2026-03-31

Net margin

0.6%

as of 2026-03-31

Price · 5Y

-35.0% / yr 48.8 pts / yr vs S&P 500 88.3% total
Compare:

Live market

delayed ≤15 min
$5.93
0.34%
Market cap
$287.9M
Enterprise value
$287.9M
P/E (trailing)
1.8×
Forward P/E
P/B
Dividend yield
4.0%
52-wk high
$14.62
52-wk low
$5.62
Beta
Shares out
48.6M

5-year trend

What this company does

AI

ITEM 1. BUSINESS Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of $1.5 billion was primarily generated by our two primary product categories: beauty products and wellness products. We operate in the direct selling channel, primarily utilizing person-to-person marketing to promote and sell our products, including through the use of social and digital platforms. In addition to our core Nu Skin business, we also explore new areas of synergistic and adjacent growth through our strategic investment arm known as Rhyz Inc., which we formed in 2018. Our Rhyz businesses…

AI summary unavailable — showing raw filing excerpt

Generated from NUS's filing dated 2026-02-13

Key risks

AI

ITEM 1A. RISK FACTORS Risk Factor Summary We are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage you to carefully review the full risk factors contained after this summary for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks include the following: Risks Associated with Direct Selling and Our Sales Force ● Challenges to the form of our network marketing system or to our business practices have harmed and could continue to harm our business. ● Direct selling laws and…

AI summary unavailable — showing raw filing excerpt

Generated from NUS's filing dated 2026-02-13

Profitability

Gross margin

69.4%

1.8%

Operating margin

4.4%

150.6%

Net margin

10.8%

227.5%

Return on equity

19.9%

188.4%

Return on assets

11.4%

214.2%

Leverage

Debt / equity

0.75×

40.6%

Long-term debt / equity

0.25×

54.6%

Debt / assets

42.7%

23.3%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$320.6M-12.0%$1.8M-98.3%0.6%

Q4 2025

2025-12-31

$370.3M-16.9%$14.5M+140.1%3.9%

Q3 2025

2025-09-30

$364.2M-15.3%$17.1M+105.7%4.7%

Q2 2025

2025-06-30

$386.1M-12.1%$21.1M+117.9%5.5%

Q1 2025

2025-03-31

$364.5M-12.7%$107.5M+20271.7%29.5%

Q4 2024

2024-12-31

$445.6M$-36.1M-8.1%

Q3 2024

2024-09-30

$430.1M-13.8%$8.3M+532.3%1.9%

Q2 2024

2024-06-30

$439.1M-12.2%$-118.3M-539.8%-26.9%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122

Your notes

Keep private notes on NUS — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$101.9K

Insider selling

$805.9K

Net activity

−$704.0K

Distinct insiders

6

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-11

Laura Nathanson

Director

Sale2,676$6.73$18.0K
2025-11-11

Steven Keith Hatchett

Chief Product Officer

Purchase5,500$9.61$52.9K
2025-09-04

Laura Nathanson

Director

Sale6,489$12.22$79.3K
2025-09-03

Chayce David Clark

EVP and General Counsel

Sale20,000$11.97$239.4K
2025-08-29

Daniel W Campbell

Director

Sale9,046$12.12$109.6K
2025-08-29

Daniel W Campbell

Director

Sale23,391$12.10$283.0K
2025-06-02

Edwina D Woodbury

Director

Sale4,532$8.44$38.3K
2025-06-02

Emma S. Battle

Director

Sale4,532$8.44$38.3K
2025-05-28

Steven Keith Hatchett

Chief Product Officer

Purchase6,500$7.54$49.0K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns NUS

Institutional value

$124.8M

Total shares held

19.0M

Distinct holders

99

-85 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1BlackRock, Inc.4.3M$31.2M-24.2K (-0.6%)Trimmed
2VANGUARD CAPITAL MANAGEMENT LLC2.1M$15.0MNew
3PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.1.8M$13.1M+60.0K (+3.5%)Added
4DIMENSIONAL FUND ADVISORS LP1.7M$12.6M+361.8K (+26.3%)Added
5VANGUARD PORTFOLIO MANAGEMENT LLC1.7M$12.4MNew
6Bank of New York Mellon Corp540.8K$3.9M-122 (-0.0%)Trimmed
7PRUDENTIAL FINANCIAL INC376.8K$2.7M+213.0K (+130.1%)Added
8Connor, Clark & Lunn Investment Management Ltd.366.0K$2.7M-44.9K (-10.9%)Trimmed
9Allianz Asset Management GmbH330.5K$2.4M+99.9K (+43.3%)Added
10VANGUARD FIDUCIARY TRUST CO309.2K$2.3MNew
11O'SHAUGHNESSY ASSET MANAGEMENT, LLC275.0K$2.0M+24.8K (+9.9%)Added
12UBS Group AG236.0K$1.7M-113.4K (-32.5%)Trimmed
13Vanguard Global Advisers, LLC229.2K$1.7MNew
14JPMORGAN CHASE & CO207.3K$1.5M-240.3K (-53.7%)Trimmed
15RITHOLTZ WEALTH MANAGEMENT179.2K$1.3M+27.3K (+18.0%)Added
16Creative Planning169.2K$1.2M+67.1K (+65.7%)Added
17WEDGE CAPITAL MANAGEMENT L L P/NC166.6K$1.2M+60.4K (+56.9%)Added
18Nuveen, LLC158.7K$1.2M+1.5K (+1.0%)Added
19Y-Intercept (Hong Kong) Ltd154.9K$1.1M+3.7K (+2.5%)Added
20STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM144.6K$1.1M-11.3K (-7.3%)Trimmed

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once NUS's latest filing finishes processing.